网站维护通知 (2025年2月22日11:15~15:30):由于系统维护,网站暂时不可用,敬请谅解!
联系方式:021-67121386 / Sales-CN@TCIchemicals.com
Maximum quantity allowed is 999
请选择数量
CAS RN: 56390-09-1 | 产品编码: E0840
Epirubicin Hydrochloride

* 点击“查询”可查看预计发货日期,仅供参考。
* 无具体发货日期的情况,如:显示“8个工作日后发货”,将在您订购日起的8个工作日后发货。
* 我们将以最优方式从上海/天津两大仓库发货。国内库存不足,需两周左右向日本总部调货。
* 对于可分装产品,11:30前的订单,当天发货;11:30后的订单,隔天发货。
* 如需大包装,请点击“大包装询价”按钮(对于某些产品我们无法提供大包装)。
* TCI会经常复审储藏条件以对其进行优化,请以在线目录为准,敬请留意。
* 更多信息,请联系营业部:021-67121386 / Sales-CN@TCIchemicals.com 。任何货期、规格或包装方面的需求,请联系我们 。
* 无具体发货日期的情况,如:显示“8个工作日后发货”,将在您订购日起的8个工作日后发货。
* 我们将以最优方式从上海/天津两大仓库发货。国内库存不足,需两周左右向日本总部调货。
* 对于可分装产品,11:30前的订单,当天发货;11:30后的订单,隔天发货。
* 如需大包装,请点击“大包装询价”按钮(对于某些产品我们无法提供大包装)。
* TCI会经常复审储藏条件以对其进行优化,请以在线目录为准,敬请留意。
* 更多信息,请联系营业部:021-67121386 / Sales-CN@TCIchemicals.com 。任何货期、规格或包装方面的需求,请联系我们 。
技术规格
Appearance | Light yellow to Yellow to Orange powder to crystal |
Purity(HPLC) | min. 95.0 area% |
Specific rotation | +310 to +340 deg(C=0.05, methanol)(calcd.on anh.substance) |
Water | max. 8.0 % |
物性(参考值)
熔点 | 185 °C |
比旋光度 [α]D | 310° (C=0.05,MeOH) |
最大吸收波长 | 497(H2O) nm |
水溶性 | 微溶 |
溶解性(微溶于) | 甲醇 |
GHS
象形图 |
![]() ![]() |
信号词 | 危险 |
危险性说明 | H302 : 吞咽有害。 H360 : 可能对生育能力或胎儿造成伤害。 H340 : 可能造成遗传性缺陷。 H350 : 可能致癌。 |
防范说明 | P501 : 将内装物/容器送到批准的废物处理厂处理。 P270 : 使用本产品时不要进食、饮水或吸烟。 P202 : 在阅读并明了所有安全措施前切勿搬动。 P201 : 使用前取得专用说明。 P264 : 作业后彻底清洗皮肤。 P280 : 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P308 + P313 : 如接触到或有疑虑:求医/就诊。 P301 + P312 + P330 : 如误吞咽:如感觉不适,呼叫急救中心/医生。漱口。 P405 : 存放处须加锁。 |
相关法规
RTECS# | QI9295750 |
新化学物质备案回执号 | B1A232215842 |
运输信息
监管条件代码(*) | Q类 (糖类,生物碱类,抗生素类,激素类) |
应用
Epirubicin Hydrochloride: An Anthracycline Antibiotic Cytotoxic Agent with a Better Toxicity Profile
Epirubicin hydrochloride is the 4’-epimer of the anthracycline antibiotic cytotoxic agent, doxorubicin [D4193]. The precise mechanisms of epirubicin’s cytotoxic and/or antiproliferative properties have not been completely elucidated. However, it has been reported that epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. After intercalation between DNA base pairs, epirubicin stabilizes the topoisomerase II-DNA complex, resulting in irreversible DNA strand breakage and cytocidal activity.1-3)
Epirubicin has been shown to have a better toxicity profile than doxorubicin. The formation of glucuronide conjugates, not seen with doxorubicin, is observed with epirubicin. The reason for this is thought to be the inversion of the OH group at the 4' position in epirubicin, which facilitates the reaction of glucuronyl transferase. This facilitates excretion and may contribute to the reduced toxicity of epirubicin compared to doxorubicin.4) In clinical, epirubicin hydrochloride has been used alone or in combination with other cytotoxic chemotherapeutic agents in the treatment of a variety of malignancies. (The product is for research purpose only.)
Epirubicin has been shown to have a better toxicity profile than doxorubicin. The formation of glucuronide conjugates, not seen with doxorubicin, is observed with epirubicin. The reason for this is thought to be the inversion of the OH group at the 4' position in epirubicin, which facilitates the reaction of glucuronyl transferase. This facilitates excretion and may contribute to the reduced toxicity of epirubicin compared to doxorubicin.4) In clinical, epirubicin hydrochloride has been used alone or in combination with other cytotoxic chemotherapeutic agents in the treatment of a variety of malignancies. (The product is for research purpose only.)
References
- 1) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
- 2) Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
- 3) Epirubicin: is it like doxorubicin in breast cancer? A clinical review
- 4) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4’-epidoxorubicin
产品文档 (部分产品的分析图谱无法提供,敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助,请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注:该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉,您搜索的分析图谱无法提供。